Curaleaf New Jersey Operations: Dispensaries, Licenses & Regulatory Status

Executive Summary

Curaleaf Holdings, Inc. operates the largest cannabis retail footprint in New Jersey, with multiple dispensaries serving both medical and adult-use customers across the state. As of May 2026, the multi-state operator maintains active licenses despite ongoing labor litigation, with the New Jersey Cannabis Regulatory Commission approving continued adult-use sales during legal proceedings. Curaleaf's New Jersey operations represent a cornerstone of the company's national strategy, generating significant revenue in one of the nation's most populous legal cannabis markets. The company entered New Jersey through its 2018 acquisition of Curaleaf New Jersey, LLC, which held one of the state's original Alternative Treatment Center licenses issued under the 2010 Compassionate Use Medical Marijuana Act. Today, Curaleaf operates cultivation facilities, processing operations, and retail locations throughout New Jersey, serving tens of thousands of registered patients and adult consumers monthly while navigating complex regulatory requirements, labor relations challenges, and intense competition from both legacy operators and new entrants in the Garden State's rapidly maturing cannabis industry.

Why Curaleaf's New Jersey Presence Matters

New Jersey's legal cannabis market generated over $1.8 billion in combined medical and adult-use sales in 2025, making it the fourth-largest state market by revenue nationally. Curaleaf's position as the dominant retailer in this market carries implications for patients, investors, competitors, and policymakers alike. For medical cannabis patients, Curaleaf's extensive retail network provides critical access to regulated products. The company serves patients with qualifying conditions including chronic pain, PTSD, anxiety disorders, and cancer, offering delivery services and compassionate pricing programs that expand access beyond traditional storefront hours. Investors monitor Curaleaf's New Jersey operations as a bellwether for multi-state operator performance in mature East Coast markets. The company's New Jersey revenue contributes substantially to its consolidated financial results, with the state representing one of Curaleaf's top three markets by revenue alongside Florida and Massachusetts. Quarterly earnings reports consistently highlight New Jersey same-store sales growth, margin performance, and market share data as key performance indicators. Competitors face Curaleaf's first-mover advantages, including prime retail locations secured under the original Alternative Treatment Center licensing regime and established brand recognition among New Jersey consumers. Smaller operators and new entrants must compete against Curaleaf's economies of scale in cultivation, processing, and marketing. The New Jersey Cannabis Regulatory Commission closely scrutinizes Curaleaf's compliance record, using enforcement actions against large operators to signal regulatory expectations industry-wide. Labor disputes, product recalls, and licensing violations involving Curaleaf often prompt broader policy discussions about workplace standards, product safety protocols, and the appropriate balance between business growth and regulatory compliance in the legal cannabis sector.

Background and History: From Medical Pioneer to Adult-Use Giant

Curaleaf's New Jersey story begins with the state's 2010 Compassionate Use Medical Marijuana Act, which created one of the nation's most restrictive medical cannabis programs.

The Alternative Treatment Center Era (2010-2018)

New Jersey Governor Jon Corzine signed the Compassionate Use Medical Marijuana Act on January 18, 2010, making New Jersey the 14th state to legalize medical cannabis. The law, codified at N.J.S.A. 24:6I-1 et seq., established a tightly controlled system limiting the number of licensed Alternative Treatment Centers to six statewide. Each ATC received exclusive rights to cultivate, process, and dispense medical cannabis within designated regions. The New Jersey Department of Health issued the first ATC licenses in 2011, with facilities beginning operations in 2012. Early ATCs operated under severe constraints: a three-strain limit, no edible products, possession limits of two ounces per month, and a narrow list of qualifying conditions. The program served fewer than 500 patients in its first year. Curaleaf New Jersey, LLC received its ATC license in 2013, initially operating a single dispensary location. The company cultivated cannabis at a secure facility in Westhampton and opened its first retail location in Bellmawr, Camden County. During this period, the program expanded slowly, with the Department of Health gradually adding qualifying conditions and increasing the strain limit to six varieties per ATC.

The Curaleaf Acquisition and Expansion (2018-2020)

Curaleaf Holdings, Inc. acquired Curaleaf New Jersey, LLC in May 2018 for approximately $40 million in stock and cash, marking the multi-state operator's entry into the Garden State. At the time of acquisition, the New Jersey ATC operated two dispensaries and served approximately 3,000 registered patients monthly. The acquisition coincided with Governor Phil Murphy's administration pushing for program expansion. In 2018 and 2019, New Jersey added qualifying conditions including anxiety, chronic pain, and migraines, while increasing possession limits and permitting edible products. The registered patient count surged from 17,000 in early 2018 to over 78,000 by the end of 2019. Curaleaf responded by expanding cultivation capacity and opening additional dispensary locations. The company opened facilities in Bordentown (Burlington County), Bellmawr (Camden County), and Edgewater Park (Burlington County), establishing a retail presence in both North and South Jersey. Cultivation operations expanded to a 75,000-square-foot facility capable of producing thousands of pounds of cannabis flower annually.

Adult-Use Legalization and Implementation (2020-2023)

New Jersey voters approved Public Question No. 1 on November 3, 2020, amending the state constitution to legalize adult-use cannabis for persons 21 and older. The referendum passed with 67% support, one of the highest approval margins for cannabis legalization in any state. The New Jersey Legislature enacted enabling legislation in February 2021, creating the Cannabis Regulatory Commission as an independent agency within the Department of the Treasury. The law, codified at N.J.S.A. 24:6I-31 et seq., established a comprehensive regulatory framework for cultivation, manufacturing, distribution, retail, and delivery of adult-use cannabis. The Cannabis Regulatory Commission issued the first adult-use retail licenses to existing ATCs on April 21, 2022, with sales beginning the same day. Curaleaf's Bellmawr location was among the first 13 dispensaries authorized to serve adult-use customers, generating over $1.9 million in sales during the first weekend of legal adult-use sales statewide. The transition to adult-use sales created operational challenges. Curaleaf and other operators faced product shortages as demand exceeded supply projections. The company prioritized medical patients through reserved inventory and dedicated service hours, while adult-use customers experienced long wait times and limited product selection during the first months of the program.

Market Maturation and Competitive Pressure (2023-2026)

The New Jersey Cannabis Regulatory Commission issued over 100 additional retail licenses between 2022 and 2025, dramatically increasing competition in the state's cannabis market. New entrants included social equity applicants, out-of-state MSOs, and New Jersey-based entrepreneurs, collectively eroding the market share of original ATCs. Curaleaf responded with aggressive expansion, opening new retail locations and investing in brand development. The company launched proprietary brands including Select (vaporizer cartridges), Curaleaf-branded flower, and Grassroots concentrates, leveraging its national product portfolio in the New Jersey market. Wholesale pricing declined sharply as cultivation capacity outpaced retail demand, with wholesale flower prices falling from approximately $3,500 per pound in early 2022 to under $1,200 per pound by late 2025. Curaleaf's vertically integrated model provided some insulation from wholesale price compression, but retail margins tightened as competitors engaged in price competition for adult-use customers. Labor organizing efforts intensified across the industry. In 2024, workers at Curaleaf's Bellmawr location filed for union representation with the United Food and Commercial Workers Local 360, citing concerns about wages, scheduling practices, and workplace safety. The National Labor Relations Board conducted an election in June 2024, with workers voting 47-23 in favor of union representation.

Recent Developments and Ongoing Litigation (2025-2026)

Curaleaf faced a significant labor lawsuit filed in New Jersey Superior Court in March 2026, alleging violations of state wage and hour laws, including failure to provide required meal breaks and improper classification of employees. The complaint, filed on behalf of current and former employees, sought class-action status and damages exceeding $2 million. The lawsuit prompted scrutiny from the Cannabis Regulatory Commission. Under N.J.A.C. 17:30-7.12, the CRC possesses authority to suspend or revoke licenses for violations of labor laws or other legal requirements. In April 2026, the CRC issued a notice of hearing to Curaleaf, requiring the company to show cause why its licenses should not be suspended pending resolution of the labor litigation. On May 14, 2026, the Cannabis Regulatory Commission voted to allow Curaleaf to continue adult-use sales during the pendency of the labor lawsuit, contingent on the company's implementation of enhanced compliance monitoring and quarterly reporting to the Commission. According to the CRC's public meeting minutes, Commissioners determined that immediate suspension would harm patients and adult-use consumers without sufficient evidence of ongoing violations warranting emergency action.

Key Players in Curaleaf's New Jersey Operations

Curaleaf Holdings, Inc.

Curaleaf Holdings, Inc. operates as the largest vertically integrated multi-state cannabis operator in the United States by revenue, with operations in 18 states and over 150 retail dispensaries nationwide. The company, headquartered in Wakefield, Massachusetts, reported $1.38 billion in revenue for fiscal year 2025, with New Jersey operations contributing an estimated $180-200 million to consolidated revenue. Executive Chairman Boris Jordan and Chief Executive Officer Matt Darin lead the company's strategic direction. Curaleaf trades on the Canadian Securities Exchange under ticker symbol CURA and on the OTCQX market under ticker CURLF, providing public market access despite federal prohibition preventing listing on major U.S. exchanges.

New Jersey Cannabis Regulatory Commission

The Cannabis Regulatory Commission serves as the independent regulatory authority overseeing all aspects of New Jersey's medical and adult-use cannabis programs. The five-member Commission, appointed by the Governor and legislative leaders, holds rulemaking authority under N.J.S.A. 24:6I-24. Executive Director Toni-Anne Blake manages day-to-day operations, overseeing licensing, compliance, enforcement, and social equity initiatives. The Commission's Enforcement Bureau investigates complaints, conducts inspections, and recommends disciplinary actions ranging from fines to license revocation.

United Food and Commercial Workers Local 360

The United Food and Commercial Workers Local 360 represents workers at multiple New Jersey cannabis facilities, including Curaleaf's Bellmawr location. The union advocates for improved wages, benefits, and working conditions in the cannabis industry, filing unfair labor practice charges and supporting legislative efforts to strengthen worker protections.

Competing Multi-State Operators

Curaleaf competes against major MSOs including Verano Holdings (Zen Leaf dispensaries), Acreage Holdings, TerrAscend, and Green Thumb Industries (RISE dispensaries) in the New Jersey market. These competitors operate vertically integrated operations similar to Curaleaf's model, with cultivation, processing, and retail capabilities. New Jersey-based operators including Ascend Wellness Holdings, Columbia Care (acquired by Cresco Labs), and Ayr Wellness also maintain significant market presence, collectively holding approximately 35% of the state's retail market share as of early 2026.

Legal and Regulatory Framework

Curaleaf's New Jersey operations function within a complex regulatory structure spanning state constitutional provisions, statutes, administrative regulations, and local ordinances. The New Jersey Constitution, Article I, Paragraph 26, as amended by the 2020 referendum, provides constitutional protection for legal cannabis activities, stating that persons 21 and older may possess and use cannabis and that the Legislature shall enact laws to regulate cultivation, processing, and sale. The New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, N.J.S.A. 24:6I-31 et seq., establishes the statutory framework for adult-use cannabis. The law created six license classes: cultivator (Class 1), manufacturer (Class 2), wholesaler (Class 3), distributor (Class 4), retailer (Class 5), and delivery (Class 6). Curaleaf holds Class 1, Class 2, and Class 5 licenses, permitting vertical integration from cultivation through retail. The Cannabis Regulatory Commission adopted comprehensive regulations codified at N.J.A.C. 17:30-1.1 et seq. These regulations specify: - Application requirements including background checks, financial disclosures, and business plans - Security standards for facilities, including surveillance systems, alarm systems, and access controls - Product testing requirements for potency, pesticides, heavy metals, microbials, and residual solvents - Packaging and labeling standards, including child-resistant packaging and THC content warnings - Inventory tracking using the METRC seed-to-sale system - Advertising restrictions prohibiting marketing to minors and health claims Labor and employment regulations impose additional requirements on cannabis operators. The New Jersey Cannabis Workforce Development Act, N.J.S.A. 24:6I-5.1 et seq., requires cannabis businesses to enter into labor peace agreements with bona fide labor organizations, prohibiting interference with unionization efforts. The law also mandates prevailing wage rates for construction projects at cannabis facilities. Municipal zoning authority permits local governments to regulate the location and number of cannabis businesses through ordinances. Curaleaf's retail locations operate in municipalities that have opted in to allowing cannabis businesses, subject to local licensing fees, operating hour restrictions, and buffer zone requirements from schools, parks, and residential areas. Tax obligations include the state's 6.625% sales tax on retail transactions, local transfer taxes up to 2% of gross receipts, and the federal 280E tax burden. Internal Revenue Code Section 280E prohibits businesses trafficking in Schedule I controlled substances from deducting ordinary business expenses, resulting in effective federal tax rates exceeding 70% for cannabis operators despite state-level legalization.

New Jersey Cannabis Market Landscape

New Jersey's legal cannabis market ranks among the nation's largest by population served and revenue generated, with unique characteristics shaped by the state's dense population, proximity to New York and Pennsylvania, and regulatory structure.

Market Size and Growth Trajectory

The New Jersey medical cannabis program served approximately 135,000 registered patients as of March 2026, with monthly sales averaging $35-40 million. Adult-use sales, which began in April 2022, reached $145-155 million monthly by early 2026, bringing combined monthly sales to approximately $185-195 million statewide. Industry analysts project New Jersey's total legal cannabis market will reach $2.1-2.3 billion in annual sales by 2027, driven by continued adult-use adoption, tourism from neighboring states, and gradual erosion of the illicit market. The state's population of 9.3 million residents provides a large customer base, with per-capita consumption rates approaching those of mature markets like Colorado and Oregon.

Curaleaf's Market Position

Curaleaf maintains the largest retail market share among New Jersey operators, estimated at 14-16% of total state sales as of Q1 2026. The company operates eight retail locations across the state, with dispensaries in Bellmawr, Bordentown, Edgewater Park, Glendale, Bloomfield, Wharton, and two locations in Paterson. Curaleaf's cultivation facilities produce an estimated 25,000-30,000 pounds of cannabis flower annually, along with significant volumes of concentrates, vaporizer cartridges, and edibles. The company supplies its own retail locations and sells wholesale to other licensed retailers, generating revenue from both retail margins and wholesale transactions. Product mix varies between medical and adult-use customers. Medical patients purchase higher ratios of CBD-rich products, tinctures, and capsules, while adult-use customers favor high-THC flower, pre-rolls, and vaporizer cartridges. Curaleaf's Select brand vaporizer cartridges rank among the top-selling products in the state, competing against brands from Verano, Rythm, and Gage.

Pricing Dynamics and Margin Pressure

Retail pricing for cannabis flower in New Jersey declined approximately 35% between April 2022 and March 2026, with eighth-ounce packages (3.5 grams) averaging $35-45 compared to $55-65 at the launch of adult-use sales. Premium strains and limited releases command higher prices, with some eighth-ounce packages priced at $55-60. Wholesale pricing compression has been more severe, with bulk flower prices falling from $3,500-4,000 per pound in early 2022 to $1,000-1,400 per pound by early 2026. Oversupply resulted from the Cannabis Regulatory Commission's aggressive licensing of cultivation facilities, with over 60 licensed cultivators operating by late 2025 compared to just 13 at the start of adult-use sales. Curaleaf's vertically integrated model provides some margin protection, as the company captures both cultivation and retail margins on products sold through its own dispensaries. However, the company faces margin pressure on wholesale sales to third-party retailers and must compete on price with other vertically integrated operators at the retail level.

What Industry Analysts and Stakeholders Say

Industry observers view Curaleaf's New Jersey operations as a critical test case for multi-state operator performance in competitive, mature markets with declining prices and increasing regulatory scrutiny. Cannabis industry analyst Matt Karnes of GreenWave Advisors noted in a March 2026 research report that Curaleaf's ability to maintain market share in New Jersey despite new competition demonstrates the value of first-mover advantages and brand recognition. According to Karnes, Curaleaf's established retail locations in high-traffic areas and its national brand portfolio provide defensible competitive advantages even as the market becomes more crowded. Labor advocates have criticized Curaleaf's employment practices and resistance to unionization efforts. Marta Rocha, organizing director for UFCW Local 360, said in a February 2026 interview with NJ Cannabis Insider that workers at Curaleaf facilities report inadequate staffing, mandatory overtime, and insufficient training on safety protocols. Rocha stated that the union would continue organizing efforts at additional Curaleaf locations and support legislative efforts to strengthen worker protections in the cannabis industry. Social equity advocates have expressed concerns about large multi-state operators like Curaleaf dominating market share at the expense of smaller, diverse-owned businesses. According to a January 2026 report from the New Jersey Cannabis Trade Association, MSOs held approximately 58% of retail market share despite representing only 22% of licensed retailers, while social equity licensees held just 8% of market share despite representing 31% of licensed retailers. Cannabis Regulatory Commission Executive Director Toni-Anne Blake addressed the Commission's decision to allow Curaleaf to continue operations during the labor lawsuit at the May 14, 2026 public meeting. According to meeting minutes, Blake stated that the Commission balanced its obligation to enforce labor law compliance against the potential harm to patients and consumers from disrupting access to a major retailer. Blake indicated that the Commission would closely monitor Curaleaf's compliance with enhanced reporting requirements and would not hesitate to take stronger enforcement action if evidence of ongoing violations emerged. Financial analysts have focused on Curaleaf's New Jersey revenue contribution and margin performance. In an April 2026 research note, Canaccord Genuity analyst Bobby Burleson estimated that Curaleaf's New Jersey operations generated approximately $48 million in revenue during Q1 2026, representing roughly 14% of the company's total revenue. According to Burleson, New Jersey margins have compressed from approximately 45% EBITDA margins in 2022 to an estimated 28-32% in early 2026, reflecting pricing pressure and increased operating costs.

What's Next: Key Developments and Decision Points

Several critical developments will shape Curaleaf's New Jersey operations over the next 12-24 months, including resolution of pending litigation, regulatory decisions on license renewals, and market dynamics as additional competitors enter the market.

Labor Lawsuit Resolution

The class-action labor lawsuit filed in March 2026 remains in the discovery phase, with a trial date tentatively scheduled for October 2026 in New Jersey Superior Court. The outcome will have significant financial and operational implications for Curaleaf. A plaintiff victory could result in substantial damages, back pay awards, and injunctive relief requiring changes to employment practices. Settlement negotiations may occur before trial, potentially resolving the matter for a confidential sum and agreement to enhanced labor practices. The Cannabis Regulatory Commission's enhanced monitoring requirements remain in effect pending lawsuit resolution. Curaleaf must submit quarterly reports detailing employee complaints, wage and hour compliance audits, and corrective actions taken. The Commission will review these reports at public meetings, with the next scheduled review in August 2026.

License Renewal Proceedings

Curaleaf's New Jersey retail licenses expire on a staggered schedule between September 2026 and March 2027, requiring renewal applications and Commission approval. The CRC conducts comprehensive reviews during renewal proceedings, examining compliance history, financial stability, and community impact. The pending labor lawsuit may factor into renewal decisions, with the Commission potentially imposing conditions such as third-party compliance monitoring or enhanced labor reporting as conditions of renewal.

Market Expansion and Competition

The Cannabis Regulatory Commission continues issuing new retail licenses, with approximately 30 additional licenses expected to become operational between mid-2026 and early 2027. These new entrants will intensify competition, particularly in North Jersey markets where Curaleaf maintains strong presence. The company may respond by opening additional locations, though market saturation concerns and declining margins may limit expansion appetite. Interstate commerce developments could significantly impact New Jersey's market dynamics. Federal rescheduling of cannabis from Schedule I to Schedule III, if finalized, would not directly authorize interstate commerce but could prompt congressional action on banking reform and interstate commerce frameworks. New Jersey's proximity to New York, Pennsylvania, and other East Coast markets positions the state as a potential hub for regional cannabis distribution if federal barriers to interstate commerce fall.

Regulatory Policy Evolution

The Cannabis Regulatory Commission has signaled potential regulatory changes in several areas affecting operators like Curaleaf. Proposed amendments to social equity regulations may impose market share caps or require large operators to partner with or support social equity licensees. The Commission is also considering enhanced labor standards, including mandatory minimum wages above state minimums and required health insurance benefits. Product regulations may evolve to address emerging categories including hemp-derived cannabinoids, high-potency concentrates, and cannabis beverages. Curaleaf's manufacturing capabilities position the company to capitalize on new product categories if regulations permit, but may also require significant compliance investments.

Further Reading and Primary Sources

• New Jersey Cannabis Regulatory Commission official website: https://www.nj.gov/cannabis/
• New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, N.J.S.A. 24:6I-31 et seq.: https://www.njleg.state.nj.us/
• Cannabis Regulatory Commission regulations, N.J.A.C. 17:30-1.1 et seq.: https://www.nj.gov/cannabis/businesses/laws-and-regulations/
• Curaleaf Holdings investor relations and financial reports: https://ir.curaleaf.com/
• New Jersey Compassionate Use Medical Marijuana Act, N.J.S.A. 24:6I-1 et seq.: https://www.njleg.state.nj.us/
• Cannabis Regulatory Commission public meeting agendas, minutes, and video archives: https://www.nj.gov/cannabis/about/commission/meetings/
• New Jersey Department of Health medical cannabis program data: https://www.nj.gov/health/medicalmarijuana/
• Internal Revenue Code Section 280E: https://www.law.cornell.edu/uscode/text/26/280E
• National Labor Relations Board case files and election results: https://www.nlrb.gov/
• New Jersey Superior Court case dockets (public access): https://www.njcourts.gov/